SLDB SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 4, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 12, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 19, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 3, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Solid Biosciences Inc. Files Prospectus Supplement for $200 Million At-the-Market Equity Offering

Aug 6, 2026

8-K

Solid Biosciences Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 10, 2026

8-K

Solid Biosciences Inc. Announces Reclassification of Director Ilan Ganot

Apr 10, 2026

8-K

Solid Biosciences Announces Positive Interim Clinical Data for SGT-003 in Duchenne Muscular Dystrophy

Mar 11, 2026

8-K

Solid Biosciences Announces $240 Million Private Placement Financing

Mar 6, 2026

8-K

Solid Biosciences Reports Q3 2025 Results and INSPIRE DUCHENNE Interim Data; FDA Pathway Update and Cash Runway Through 1H 2027

Nov 3, 2025

Prospectus

TYPE

HEADLINE

FILED AT

424B5

[No Baby Shelf]* August 2026 ATM | Offering amount: $200,000,000 | Bank: Jefferies LLC

Aug 6, 2026

424B7

SHARE RESALE REGISTRATION | Shares: 42,780,739

Jun 5, 2026

424B5

May 2025 ATM | Amount sold to date: $10,464,142

May 15, 2025

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Feb 18, 2025

424B5

ATM | Offering amount: $24,183,414 | Amount sold to date: $0 | Float: 9,349,258

Mar 23, 2023

424B5

21,739,131 Shares-

Mar 19, 2021

Registrations

TYPE

HEADLINE

FILED AT

S-3ASR

August 2026 SHELF

Aug 6, 2026

S-3

SHARE RESALE REGISTRATION

Mar 19, 2026

S-3

SHARE RESALE REGISTRATION

Mar 19, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 19, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jun 13, 2025

S-3

May 2025 SHELF

May 15, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 23, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 23, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Apr 10, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 25, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 25, 2025

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Apr 11, 2025

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13D/A

RA CAPITAL MANAGEMENT, L.P. (Filed by)

Nov 6, 2026

Ganot Ilan (Reporting)

Oct 26, 2026

Brooks Gabriel (Reporting)

Oct 20, 2026

SMITH IAN F (Reporting)

Oct 6, 2026

SCHEDULE 13D/A

PERCEPTIVE ADVISORS LLC (Filed by)

Aug 14, 2026

SCHEDULE 13G/A

Vestal Point Capital, LP (Filed by)

Aug 14, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 1, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 1, 2026

CORRESP

Form CORRESP - Correspondence

Mar 27, 2026

CORRESP

Form CORRESP - Correspondence

Mar 27, 2026

LETTER

Form UPLOAD - SEC-generated letter

Mar 24, 2026

LETTER

Form UPLOAD - SEC-generated letter

Mar 24, 2026

Solid Biosciences Inc. SLDB · SEC Filings